Abstract
BACKGROUND Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
